Drug Topics
SEPTEMBER 20, 2024
In its first move since the July interim report detailing pharmacy benefit manager practices, the FTC is now suing CVS Caremark, Express Scripts, and Optum Rx.
Fierce Healthcare
SEPTEMBER 20, 2024
The Federal Trade Commission is suing the titans of the pharmacy benefit manager industry for anticompetitive practices and artificially raising the price of insulin drug prices, the agency announc | As expected for weeks, the Federal Trade Commission is taking legal action against the biggest three PBMs and its related group purchasing organizations.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
SEPTEMBER 20, 2024
A second health worker who cared for a person hospitalized in Missouri with H5N1 bird flu developed mild respiratory symptoms but was not tested for influenza, the Centers for Disease Control and Prevention reported on Friday. The CDC said Missouri health officials didn’t learn that the health worker had symptoms until after the individual had recovered, too late to run a diagnostic test.
Drug Topics
SEPTEMBER 20, 2024
Johnny Garcia, Senior Director of Policy at the Pharmaceutical Care Management Association, discussed the common misconceptions surrounding PBMs and their role within the supply chain.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
SEPTEMBER 20, 2024
The U.S. Federal Trade Commission filed a lawsuit against the largest pharmacy benefit managers and their group purchasing organizations for allegedly anticompetitive practices that “artificially inflated” the price of insulin and, consequently, impeded patient access to the life-saving treatment. The administrative complaint accused CVS Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx of creating a “perverse” system of rebates that favored
Drug Topics
SEPTEMBER 20, 2024
Stephanie Sober, MD, MSHP, shares insights into the research that led to Opill’s FDA approval and its implications for women’s access to contraception.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
SEPTEMBER 20, 2024
“By encouraging active self-management using health coaching principles, the WalkBack intervention might be able to reduce the prevalence of recurrent low back pain and associated burden on health care systems,” wrote investigators.
Pharmacy Times
SEPTEMBER 20, 2024
The chief product and strategy officer at Linus Health is hopeful that pharmacists can be key players in the detection of mild cognitive impairment.
STAT
SEPTEMBER 20, 2024
In 2013, I sat down at my computer and secured the URL t1international.com. I wanted a place where I could collect and share everything I was learning about the global insulin price crisis. I was only 25 years old, and I had already been living with type 1 diabetes for more than two decades. I had struggled with the ups and downs of high and low blood sugars, been hospitalized multiple times, and faced wildly high costs for my insulin and diabetes supplies in the United States.
Pharmacy Times
SEPTEMBER 20, 2024
The decision expands treatment options for patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM).
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
STAT
SEPTEMBER 20, 2024
As a pediatrician working for NYC Health + Hospitals (H+H), one of the largest public health care systems in the country, I have witnessed firsthand the challenges of providing quality care to patients from all walks of life. Whether they’re American-born or newly arrived children, my colleagues and I are tasked with ensuring they get the medical attention they need.
Fierce Pharma
SEPTEMBER 20, 2024
The hits just keep on coming for Bristol Myers Squibb staffers amid the company's cost-savings program. | Bristol Myers Squibb is laying off an additional 79 staffers in Lawrenceville, New Jersey. The cuts will be effective between Dec. 12 and May 30 of next year and are part of BMS's $1.5 billion cost reduction program.
Pharmacy Times
SEPTEMBER 20, 2024
Amivatamab-vmjw is a fully-human bispecific antibody targeting EGFR and MET with immune cell-directed activity.
Fierce Healthcare
SEPTEMBER 20, 2024
Cigna is reshaping its Medicare Advantage (MA) plan lineup across eight states, affecting members in 36 health plans. | Cigna is the latest company to rethink its Medicare Advantage offerings, choosing to cut plans in eight states including Florida.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
STAT
SEPTEMBER 20, 2024
A next-generation obesity drug candidate from Novo Nordisk produced modest weight loss, along with a higher rate of some psychiatric side effects like anxiety and sleep disturbances — results that pose a challenge to the pharma giant’s efforts to find novel obesity drugs that could extend its success from its blockbuster Wegovy. A Phase 2a trial tested monlunabant, a pill that inhibits CB1 receptors that Novo got through its acquisition of Inversago Pharma last year.
Pharmacy Times
SEPTEMBER 20, 2024
The rare disease can result in progressive neurological symptoms and organ complications.
Drug Topics
SEPTEMBER 20, 2024
Zevra Therapeutics said it expects the therapy to be commercially available in the United States in 8 to 12 weeks.
Fierce Healthcare
SEPTEMBER 20, 2024
The country’s third-largest nonprofit health system announced Thursday it will strike all judgment liens on patients’ homes and real estate, as well as eliminate the associated outstanding debts fo | The major nonprofit health system said the plan builds on its post-merger charity care policy changes, and will help improve access and affordability of care.
Pharmacy Times
SEPTEMBER 20, 2024
Dermatomal reactions could occur following recombinant zoster vaccine to treat shingles.
STAT
SEPTEMBER 20, 2024
The Food and Drug Administration has tapped Ross Segan, a former device industry exec and Army veteran, to lead its division charged with ensuring medical device safety. Segan was chief medical officer at Olympus from 2020 to 2023. Olympus is a leading distributor of endoscopes and the recipient of FDA warning letters claiming the company did not adequately address product defects — including instances where endoscope caps fell into patients’ bodies.
The Checkup by Singlecare
SEPTEMBER 20, 2024
If you get heartburn after eating some of your favorite foods—like fried chicken or pasta— omeprazole can be a lifesaver, helping prevent painful symptoms. But what if you want to have a beer or a glass of wine along with your meal? Can you safely mix omeprazole and alcohol? The short answer is yes; there is no interaction between the two. However, most healthcare providers recommend against drinking while taking this medication—also known by its brand names Prilosec and Zegerid.
Fierce Pharma
SEPTEMBER 20, 2024
Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of AstraZeneca’s Tagrisso in non-small cell lung cancer (NSCLC). | Approvals are coming fast and furious for Johnson & Johnson’s Rybrevant as it is lining up to challenge the dominance of AstraZeneca’s Tagrisso in non-small cell lung cancer (NSCLC).
STAT
SEPTEMBER 20, 2024
Amazon is terminating its contract with Progyny, a company that sells fertility benefits such as in vitro fertilization and egg freezing to employers, according to a source familiar with the matter. Starting Jan. 1, 2025, Amazon employees will no longer have access to Progyny’s services. Instead, Amazon will use Maven as its fertility benefits vendor, the person said.
Fierce Pharma
SEPTEMBER 20, 2024
Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been left in the cold once again. | Europe’s Committee for Medicinal Products for Human Use has confirmed its negative stance on pegcetacoplan in geographic atrophy, an advanced form of age-related macular degeneration that can lead to blindness.
STAT
SEPTEMBER 20, 2024
WASHINGTON — A federal appeals court ruled that three organizations, including the brand drug lobby PhRMA, can challenge Medicare’s drug price negotiation program in a lower court based in Texas.
Drug Topics
SEPTEMBER 20, 2024
Check out important updates from the FDA for the week of September 16.
Pharmacy Times
SEPTEMBER 20, 2024
Ponsegromab displayed significant and robust increases in body weight at the completion of the study for all doses.
pharmaphorum
SEPTEMBER 20, 2024
Astellas is ready to launch its first digital health product in the US, called Digitiva, which provides at-home monitoring of people with heart failure
Pharmacy Times
SEPTEMBER 20, 2024
Improvements in survival outcomes were seen among those at high risk for DLBCL who received 6x R-CHOP21 + 2R.
pharmaphorum
SEPTEMBER 20, 2024
J&J's target of $5bn in sales for Rybrevant has moved a step closer, after an FDA approval for second-line treatment of EGFR+ NSCLC
Fierce Pharma
SEPTEMBER 20, 2024
For Zevra Therapeutics and its rare neurodegenerative disease med arimoclomol, the second time’s the charm. | The FDA approved Zevra’s arimoclomol capsules to treat the rare lysosomal storage disorder Niemann-Pick disease type C in conjunction with Johnson & Johnson’s enzyme inhibitor miglustat. Arimoclomol, which will fly under the brand name Miplyffa, is now the first FDA-approved therapy for NPC.
STAT
SEPTEMBER 20, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning! Today, we see Ginkgo pivot into AI, becoming yet another contender in a crowded market. Also, we see more documents destroyed at an Indian drug manufacturing plant, and offer up a fabulous podcast.
Drug Topics
SEPTEMBER 20, 2024
The vaccine will be made available via third-party online pharmacies.
STAT
SEPTEMBER 20, 2024
If you’re a health care worker who vibes with this Tiktok , have I got a newsletter for you: STAT’s Health Care, Inc. by Bob Herman (#BobHive rise up), who makes the crushing monetization of our health at least kind of fun? (Important info: If you’re already a subscriber to HCI, get a friend to sign up at this link with the referral code provided in Monday’s newsletter and be entered to win a $100 bookshop.org gift certificate!
Expert insights. Personalized for you.
187 
Let's personalize your content